The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma

References

• Nakai R, Iida S, Takahashi T, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 2009;69:3901–3909.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006;16:1194–1200.
   PubMed Web of Science ®Google Scholar
• Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol 2005;15:467–476.
   PubMed Web of Science ®Google Scholar
• Vale RD, Reese TS, Sheetz MP. Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell 1985;42:39–50.
   PubMed Web of Science ®Google Scholar
• Sawin KE, LeGuellec K, Philippe M, et al. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992;359:540–543.
   PubMed Web of Science ®Google Scholar
• Kapitein LC, Peterman EJ, Kwok BH, et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435:114–118.
   PubMed Web of Science ®Google Scholar
• Kashina AS, Rogers GC, Scholey JM. The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation. Biochim Biophys Acta 1997;1357:257–271.
   PubMed Web of Science ®Google Scholar
• Hagan I, Yanagida M. Novel potential mitotic motor protein encoded by the fission yeast cut7 + gene. Nature 1990;347:563–566.
   PubMed Web of Science ®Google Scholar
• Heck MM, Pereira A, Pesavento P, et al. The kinesin-like protein KLP61F is essential for mitosis in Drosophila. J Cell Biol 1993;123: 665–679.
   PubMed Web of Science ®Google Scholar
• Hoyt MA, He L, Loo KK, et al. Two Saccharomyces cerevisiae kinesin-related gene products required for mitotic spindle assembly. J Cell Biol 1992;118:109–120.
   PubMed Web of Science ®Google Scholar
• Kapoor TM, Mayer TU, Coughlin ML, et al. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975–988.
   PubMed Web of Science ®Google Scholar
• Zhu C, Zhao J, Bibikova M, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005;16: 3187–3199.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Gerecitano J, Van Deventer H, et al. The addition of G-CSF shifts the dose limiting toxicity (DLT) and markedly increases the maximum tolerated dose (MTD) and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study. Leuk Lymphoma 2015;10:1–25.
   Google Scholar
• Paoluzzi L, Scotto L, Marchi E, et al. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol 2009;146:656–659.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Scotto L, Marchi E, et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010;16:554–565.
   PubMed Web of Science ®Google Scholar
• Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010;16:3648–3658.
   PubMed Web of Science ®Google Scholar
• Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011;118:5506–5516.
   PubMed Web of Science ®Google Scholar
• Amengual JE, Clark-Garvey S, Kalac M, et al. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood 2013;122:2104–2113.
   PubMed Web of Science ®Google Scholar
• Liu M, Aneja R, Liu C, et al. Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 2006;281: 18090–18097.
   PubMed Web of Science ®Google Scholar
• Huang HC, Shi J, Orth JD, et al. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009;16:347–358.
   PubMed Web of Science ®Google Scholar
• Reck-Peterson SL, Yildiz A, Carter AP, et al. Single-molecule analysis of dynein processivity and stepping behavior. Cell 2006; 126:335–348.
   PubMed Web of Science ®Google Scholar
• Liu AM, Lo RK, Wong CS, et al. Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J Biol Chem 2006;281:35812–35825.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464–470.
   PubMed Web of Science ®Google Scholar
• de Leval L, Braaten KM, Ancukiewicz M, et al. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 2003;27:1269–1277.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747–752.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991–9996.
   PubMed Web of Science ®Google Scholar
• Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122(Pt 15):2579–2585.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim S, Cho H, et al. Depletion of BubR1 promotes premature centrosomal localization of cyclin B1 and accelerates mitotic entry. Cell Cycle 2009;8:1754–1764.
   PubMed Web of Science ®Google Scholar
• Huang H, Yen TJ. BubR1 is an effector of multiple mitotic kinases that specifies kinetochore: microtubule attachments and checkpoint. Cell Cycle 2009;8:1164–1167.
   PubMed Web of Science ®Google Scholar